Joan Smith spent almost 40 years believing she suffered from severe allergies. Medical professionals frequently dismissed her ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders.

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC ) today announced that company management will participate virtually in a fireside chat at the 24 th ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Blueprint Medicines Corporation (NASDAQ:BPMC) ...

Healthcare Analysts provide expert insights on current and emerging treatments for Systemic Mastocytosis (relevant companies Blueprint ...

Routine screening tests may reveal findings that lead to an incidental diagnosis of SM. A middle-aged woman was diagnosed with indolent systemic mastocytosis (SM) following investigations after an ...

The company’s primary revenue driver, Ayvakit, has been approved for the treatment of indolent systemic mastocytosis (ISM) and advanced systemic mastocytosis (ASM), positioning Blueprint at the ...

A Federal Court judge on Monday dismissed a motion to certify a proposed class-action lawsuit launched by Black public servants in 2020 who alleged there was systemic racism within the public service.

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors with a PDGFRA exon 18 mutation as well advanced systemic mastocytosis and ...